ALLMedicine™ Systemic Mastocytosis Center
Research & Reviews 361 results
https://doi.org/10.1038/s41375-021-01406-y 10.1016/S0145-2126(01)00038-8 10.1111/j.1365-2362.2007.01807.x 10.1016/S0145-2126(01)00028-5 10.1073/pnas.92.23.10560 10.1038/leu.2015.24 10.1016/j.jaci.2004.02.045 10.1158/0008-5472.CAN-16-2234 10.1182/blood-2016-09-731893 10.1182/blood-2006-06-028100 10.1016/j.jaci.2010.02.019 10.1182/blood-2009-10-249979 10.3324/haematol.2010.034553 10.1016/j.jaci.2013.06.020 10.1111/cea.12369 10.1016/j.bone.2011.07.004 10.1182/blood-2006-04-015545 10.1016/j.jaci.2009.05.003 10.1111/all.14248 10.1016/j.jaip.2018.09.024 10.1016/S2352-3026(19)30166-8 10.1111/1523-1747.ep12468882 10.1016/j.jaci.2008.11.018 10.1002/ajh.24382 10.1182/blood-2009-02-205237 10.1038/leu.2016.190 10.7150/thno.51872 10.1200/JCO.19.00640 10.1182/bloodadvances.2018026245 10.1016/S2352-3026(20)30400-2 10.1111/all.12409 10.1038/leu.2015.284 10.1182/blood.2018886507 10.1038/modpathol.2011.84 10.1159/000059404 10.1016/j.iac.2018.04.003 10.1111/bjh.17567
Leukemia Zanotti R, Bonifacio M et. al.
Sep 22nd, 2021 - In the current classification of the World Health Organization (WHO), bone marrow mastocytosis (BMM) is a provisional variant of indolent systemic mastocytosis (ISM) defined by bone marrow involvement and absence of skin lesions. However, no addit...
Blood Henriques A, Muñoz-González JI et. al.
Sep 9th, 2021 - Circulating tumor mast cells (CTMC) have been identified in the blood of a small number of patients with advanced systemic mastocytosis (SM). However, limited data exists about their frequency and prognostic impact in patients with mast cell activ...
Molecular Oncology; Kim JO, Kim KH et. al.
Aug 19th, 2021 - c-Kit overexpression and activating mutations, which are reported in various cancers, including gastrointestinal stromal tumor (GIST), small-cell lung cancer (SCLC), acute myeloid leukemia, acral melanoma, and systemic mastocytosis (SM), confer re...
Molecular Therapy : the Journal of the American Society O... Snider DB, Arthur GK et. al.
Aug 10th, 2021 - Activating mutations in c-KIT are associated with the mast cell (MC) clonal disorders cutaneous mastocytosis and systemic mastocytosis and its variants, including aggressive systemic mastocytosis, MC leukemia, and MC sarcoma. Currently, therapies ...
Expert Review of Hematology; Bose P, Verstovsek S
Jul 23rd, 2021 - Systemic mastocytosis (SM) is a rare myeloid neoplasm driven in ≈95% of cases by activating KIT mutations, usually D816V. SM can be indolent (ISM), smoldering (SSM) and advanced (AdvSM), the latter characterized by organ damage resulting from infi...
Guidelines 1 results
Journal of the National Comprehensive Cancer Network : JN... Gotlib J, Gerds AT et. al.
Dec 14th, 2018 - Mastocytosis is a group of heterogeneous disorders resulting from the clonal proliferation of abnormal mast cells and their accumulation in the skin and/or in various extracutaneous organs. Systemic mastocytosis is the most common form of mastocyt...
Drugs 181 results see all →
News 30 results
CHEST Physician; Richard Mark Kirkner
Mar 31st, 2020 - A small-molecule kinase inhibitor that targets a gene mutation complicit in systemic mastocytosis has been found to reduce symptoms by about 30%, according to early results of a clinical trial scheduled to be presented at the American Academy of A.
Dec 8th, 2018 - Photo by Jen Smith Jason R. Gotlib, MD SAN DIEGO—The KIT D816V inhibitor avapritinib can improve symptoms of systemic mastocytosis (SM), according to researchers.
Liman AD, Gandhi A et. al.
Sep 14th, 2018 - Introduction: Systemic mastocytosis (SM) is a rare myeloid neoplasm that is caused by accumulation of abnormal mast cells in the bone marrow, liver, spleen, and skin. The KIT D816V mutation encodes a constitutively activated receptor tyrosine kina.
Jun 25th, 2018 - Photo from EHA Poster session at the 23rd Congress of the European Hematology Association (EHA) STOCKHOLM—The KIT/PDGFRA inhibitor avapritinib has produced durable responses in patients with systemic mastocytosis (SM). In the phase 1 EXPLORER tria.
Mar 2nd, 2018 - Moreover, four of the nine patients with persistent mast cell-rich synovitis after 6 months of synthetic DMARDs had synovial lymphoid aggregates of CD20-positive B cells and/or CD138-positive plasma cells; in contrast, none of the 11 synovial mast.